When standard cancer treatment stops working, the next step can feel hard to see. You may be trying to understand clinical trials, new test results, and treatment options at a time when you already have a lot on your mind.
RareCan helps you find clinical trials and treatment options with information that is clear, respectful, and grounded in what makes your cancer unique. In this guide, you’ll see how to organise the search, what to ask about clinical trials, and where tumour genomic testing may help you and your clinician understand what could come next.
Quick Guide: How to find clinical trials and treatment options after standard cancer treatment in 6 easy steps
- Clarify what has changed: Put the current situation into clear, simple words.
- Gather your clinical information: Pull together the records that shape your options.
- Ask whether tumour genomic testing is relevant: See if test results could widen the search.
- Focus on treatment trials that match your situation: Look for trials that fit your diagnosis and history.
- Review eligibility criteria with care: Check the details before assuming a trial fits.
- Turn the findings into a clinician conversation: Bring a clear summary to your next appointment.
1. Clarify what has changed
Start by putting the situation into plain language. That may mean a treatment is no longer controlling the cancer, side effects have become too difficult, or your clinician has explained that the current plan has reached its limit.
This matters because different situations can lead to different next steps. A search for clinical trials after disease progression is different from a search prompted by side effects, a rare tumour subtype, or a new biomarker result.
If you can explain what has changed in one or two short sentences, the next conversation often becomes easier. It gives you and your clinician a clearer place to begin.
2. Gather your clinical information
Before you start looking for treatment options, collect the details that shape what is realistic. This often includes your diagnosis, stage, past treatments, recent scans, pathology findings, and any earlier genetic or molecular reports.
If your records feel scattered, that is okay. A short list is enough to start. A simple summary can make it easier to discuss a personalised trial report, a referral, or further testing without having to repeat everything each time.
You do not need to have every document perfectly arranged. You only need enough information to keep the search grounded in your actual cancer history.
3. Ask whether tumour genomic testing is relevant
What many people call cancer genetic testing is often tumour genomic testing. This means testing the cancer itself, rather than looking for inherited family risk.
That information can sometimes help identify targeted treatment options or clinical trials that would be hard to spot from diagnosis alone. It can also show limits. Not every cancer releases enough DNA into blood, and not every result opens a new path.
If testing is relevant, ask what kind of result would change the next conversation. For some people, a broader profile such as blood-based tumour profiling may add useful detail for clinical trial matching and treatment discussions.
4. Focus on treatment trials that match your situation
A long list of clinical trials is rarely what you need. The more useful question is which trials match your cancer type, stage, treatment history, location, and any known biomarkers.
This is where curation can help. RareCan provides a UK-focused clinical trial support service designed to help people move from broad searching to a shorter list that can support a real referral discussion.
It can also help to understand how genomics fits into trial access more broadly. The NHS has described how genomic pathways can support earlier and more equitable access to trials for some people with cancer.
5. Review eligibility criteria with care
A trial can look right at first glance and still turn out not to fit. Eligibility criteria often depend on past treatment lines, performance status, organ function, measurable disease, timing, and exact biomarker definitions.
This is one reason treatment decisions need detail. Cancer Research UK’s DETERMINE precision medicine trial shows how some UK pathways use genomic alterations to guide access, but formal criteria still decide who can take part.
If a study looks promising, ask what might exclude you as well as what might include you. That is often where the clearest answer sits.
6. Turn the findings into a clinician conversation
You do not need to carry the whole decision alone. The aim is to arrive at your next appointment with a clear summary of what you found and the questions that still need answers.
That summary might include possible clinical trials, the role of InsightDecode if you already have a genomic report, or whether further molecular testing could help clarify what comes next. A short note can make your discussion with your clinician more productive.
Good information does not take away uncertainty. It can help you feel better prepared for the next decision, and that matters.
What is the difference between a broad trial search and a realistic shortlist?
A broad trial search shows what exists. A realistic shortlist looks at which clinical trials may fit your diagnosis, treatment history, biomarkers, and referral pathway.
This matters because public trial listings can be hard to interpret in context. Some studies are open on paper but not realistic for your situation. Others may only become relevant after a specific tumour genomic testing result.
That is why a structured review is often more helpful than a longer list. You need a smaller number of options that can support a real clinical conversation.
When can tumour genomic testing help you find clinical trials?
Tumour genomic testing can help when the result adds information that may affect treatment or trial matching. That may include identifying an actionable alteration, ruling out one path, or showing where further questions are worth asking.
It is still important to stay realistic. Testing does not guarantee a treatment, a referral, or a place on a trial. Its value is in giving you and your clinician a clearer view of your cancer biology and how that may connect to available options.
How RareCan helps you find clinical trials and treatment options
RareCan gives you more than a general search. We help you understand, find, and navigate clinical trials as potential treatment options, with support that is clear, respectful, and without pressure.
For people who need a focused review of UK trial options, Personalised Trial Report helps turn diagnosis and treatment history into a curated shortlist. For people who already have genomic results, InsightDecode translates complex findings into plain English and matches known biomarkers to UK-relevant treatment and trial options.
RareCan also offers tumour genomic testing to help you and your clinician understand more about the biology of your cancer. If you want a clearer starting point for the next conversation, RareCan helps you move from uncertainty to a more informed shortlist.
FAQs about the topic
Yes, sometimes you can. Trial timing depends on your diagnosis, treatment history, and the rules of the specific study. RareCan helps you assess trial timing so you and your clinician can discuss options before a rushed decision is needed.
No, it does not. Tumour genomic testing can reveal information that supports treatment or trial discussions, but it does not guarantee access, eligibility, or benefit. RareCan provides tumour genomic testing to give you clearer information for the next conversation.
You may still be able to use it. RareCan translates existing genomic reports into plain English and uses known biomarkers to explore UK-relevant treatment and clinical trial options.
Many treatment trials do not charge participants for the study treatment itself, but practical arrangements vary by trial and site. It is still worth asking about travel, appointments, and referral steps so the full commitment is clear.
Bring a short treatment history, recent scan or pathology summaries, and any genomic reports you already have. That gives the conversation a factual base and makes it easier to judge whether further testing or trial review is relevant.